Trial Profile
Real World study of Infliximab Biosimilar of Planserv Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research